Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

Daniel P. Petrylak, Robert B. Macarthur, John O'Connor, Gary Shelton, Timothy Judge, Joshua Balog, Charles Pfaff, Emilia Bagiella, Daniel Heitjan, Robert Fine, Nancy Zuech, Ihor Sawczuk, Mitchell Benson, Carl A. Olsson

Research output: Contribution to journalArticle

286 Scopus citations

Abstract

Purpose: To evaluate the toxicity, efficacy, and pharmacokinetics of docetaxel when combined with oral estramustine and dexamethasone in a phase I study in patients with progressive metastatic androgen-independent prostate cancer. Patients and Methods: Thirty-four men were stratified into minimally pretreated (MPT) and extensively pretreated (EPT) groups. Estramustine 280 mg PO tid was administered 1 hour before or 2 hours after meals on days i through 5, with escalated doses of docetaxel from 40 to 80 mg/m2 on day 2. Treatment was repeated every 21 days. Results: Thirty-four patients were assessable for toxicity and 33 for response. In the MPT patients, dose- limiting myelosuppression was reached at 80 mg/m2, with six patients experiencing grade 3/4 granulocytopenia. In EPT patients, escalation above 70 mg/m2 was not attempted. Fourteen MPT (70%) and six EPT (50%) patients had a ≥ 50% decline in serum PSA on two consecutive measurements taken at least 2 weeks apart. The overall 50% PSA response rate was 63% (95% confidence interval [CI], 28% to 81%). Of the 18 patients with bidimensionally measurable disease, five (28%; 95% CI, 11% to 54%) achieved a partial response. At the time of entry onto the study, 15 patients required narcotic analgesics for bone pain; after treatment, eight (53%) discontinued their pain medications. The area under the curve for docetaxel increased linearly from 40 to 70 mg/m2. At 80 mg/m2, the measured area under the curve was 8.37 (standard deviation, 0.724), which was significantly higher than the previously reported values. Conclusion: The recommended phase II dose of docetaxel combined with estramustine is 70 mg/m2 in MPT patients and 60 mg/m2 in EPT patients. This combination is active in men with androgen- independent prostate cancer.

Original languageEnglish (US)
Pages (from-to)958-967
Number of pages10
JournalJournal of Clinical Oncology
Volume17
Issue number3
DOIs
StatePublished - Mar 1999

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Petrylak, D. P., Macarthur, R. B., O'Connor, J., Shelton, G., Judge, T., Balog, J., Pfaff, C., Bagiella, E., Heitjan, D., Fine, R., Zuech, N., Sawczuk, I., Benson, M., & Olsson, C. A. (1999). Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. Journal of Clinical Oncology, 17(3), 958-967. https://doi.org/10.1200/jco.1999.17.3.958